|
|
|
Volumn 104, Issue 3 II, 1999, Pages 610-613
|
|
A look at the future of pediatric therapeutics: An investigator's perspective of the new pediatric rule
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
AMINOGLYCOSIDE ANTIBIOTIC AGENT;
AMPICILLIN;
BETA LACTAM ANTIBIOTIC;
CEFTRIAXONE;
CHLORAMPHENICOL;
CORTICOTROPIN;
COTRIMOXAZOLE;
DIDANOSINE;
GANCICLOVIR;
INDINAVIR;
ISONIAZID;
KANAMYCIN;
LAMIVUDINE;
NELFINAVIR;
NEVIRAPINE;
PENICILLIN G;
PYRAZINAMIDE;
RIFAMPICIN;
RITONAVIR;
SAQUINAVIR;
STAVUDINE;
STREPTOMYCIN;
SULFADIAZINE;
TERBINAFINE;
TETRACYCLINE;
ZIDOVUDINE;
ANEMIA;
ANTIBIOTIC RESISTANCE;
BLOOD DYSCRASIA;
BUDGET;
CHILD CARE;
CHILD DEATH;
CONFERENCE PAPER;
DOSE CALCULATION;
DRUG INDICATION;
DRUG INDUCED DISEASE;
DRUG LEGISLATION;
DRUG RESEARCH;
GOVERNMENT;
GRAND MAL SEIZURE;
LIVER TOXICITY;
PENICILLIN ALLERGY;
PRIORITY JOURNAL;
TOOTH COLOR;
ANTI-INFECTIVE AGENTS;
CHILD;
DRUG INDUSTRY;
DRUG LABELING;
DRUG THERAPY;
HUMANS;
INFANT;
LEGISLATION, DRUG;
PEDIATRICS;
UNITED STATES;
|
|
EID: 0032888041
PISSN: 00314005
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (15)
|
|
References (0)
|
